Results 251 to 260 of about 5,496,645 (302)
Some of the next articles are maybe not open access.
PROGESTAGENS AND ADVANCED BREAST CANCER
The Lancet, 1971Abstract An interim analysis of the clinical responses in a controlled trial of œstrogens, an androgen, or a progestagen in the treatment of advanced breast cancer suggests that the progestagen used (17α-hydroxyprogesterone caproate 250 mg. intramuscularly three times a week) has no place in the management of generalised disease.
V, Jones +7 more
openaire +2 more sources
Locally advanced breast cancer
Current Treatment Options in Oncology, 2000Over the past 20 years, the prognosis for women diagnosed with locally advanced breast cancer (LABC; clinical stages IIB through IIIB) has improved significantly with recognition of the efficacy of multimodal therapy for reducing both local and distant recurrences, even in patients with inflammatory breast cancer (IBC).
openaire +2 more sources
The control of advanced breast cancer
The American Journal of Surgery, 1963Abstract The control of breast cancer is now a three stage process. The initial surgical attack, irradiation therapy and chemotherapy. All must be employed. The consideration of various hormonal therapies and chemotherapies requires a thorough knowledge of the effectiveness of each individual therapy.
openaire +2 more sources
Olaparib for Advanced Breast Cancer
Future Oncology, 2020Olaparib, an oral PARP-inhibitor, has shown clinical benefit for HER2-negative advanced breast cancer patients carrying a germinal BRCA1/2 mutation. In a randomized Phase III trial, olaparib significantly prolonged progression-free survival as compared with chemotherapy of physician choice.
Gaia, Griguolo +4 more
openaire +2 more sources
Gemcitabine in advanced breast cancer
Anti-Cancer Drugs, 1995The experience with single-agent gemcitabine in advanced or metastatic breast cancer is reviewed. In all studies, gemcitabine was administered as a 30 min intravenous infusion in cycles once a week for 3 weeks followed by 1 week of rest. In the first European study (gemcitabine 800 mg/m2/week), of 40 evaluable patients, 14 were chemo-naive, 7 had ...
openaire +2 more sources
Adrenalectomy in advanced cancer of the breast
The American Journal of Surgery, 1957Abstract 1. 1. A case of far advanced carcinoma of the breast is presented, in which adrenalectomy and oophorectomy produced dramatic results. 2. 2. This modality of therapy should at least be considered in all apparently hopeless cases of carcinoma of the breast. 3. 3. One should not underestimate the value of palliative surgery.
openaire +2 more sources
Management of Advanced Breast Cancer
Hormone Research, 2008The systemic treatment of advanced breast cancer is not curative in intent but steady progress is being made which should lessen the morbidity from metastatic disease. Reference has been made to relevant posters presented at the International Symposium on Endocrine Therapy.
openaire +2 more sources
The Management of Advanced Cancer of the Breast
Radiology, 1948Radiologists see more cancer than anyone else and therefore are believed by the public and by some of their colleagues to be experts. Although they are not ordinarily required to undertake the general care of cancer patients, their opinion is often sought on the advisability of various surgical and radiological procedures, as well as the problems that ...
openaire +2 more sources
Aminoglutethimide in Advanced Breast Cancer
Tumori Journal, 1985From July 1980 to June 1983, 61 postmenopausal women with progressive metastatic breast cancer were treated with aminoglutethimide, 250 mg 4 times daily, plus cortisone acetate, 25 mg twice daily. Of 51 evaluable patients, an objective remission was observed in 22 (43 %) (partial remission in 19, complete in 3), stable disease in 14 (27 %), and ...
G, Ceci +4 more
openaire +2 more sources
Advances in Immunotherapy for Breast Cancer
ONCOLOGYImmunotherapy has transformed the treatment of a variety of malignancies, including breast cancer. Given the unmet clinical need, immunotherapy was first studied in advanced-stage, triple-negative breast cancer (TNBC). The anti-PD-1 agent pembrolizumab plus chemotherapy is approved for both advanced and early TNBC, and data from randomized phase 3 ...
Sarah, Poland +2 more
openaire +2 more sources